| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
1 Departments of Pathology,
2 Medicine, and
3 Dermatology, Yale University School of Medicine, New Haven, Connecticut, and
4 The Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York
The transcription factor activating transcription factor 2 (ATF2) has been shown to be associated with melanocytic oncogenesis and melanoma tumor proliferation in preclinical models. The clinical significance of ATF2 expression is unknown. To determine the prognostic value of ATF2 in melanoma, we evaluated the pattern and level of ATF2 expression in a large cohort of melanoma specimens. Immunohistochemical staining was performed on a tissue microarray representing 544 patients with a mean follow-up time of 60 months. Expression was evaluated semiquantitatively and correlated with overall survival and other clinicopathological data. Strong cytoplasmic ATF2 expression was associated with primary specimens rather than metastases (P < 0.0001) and with better survival (P = 0.0003). Strong nuclear ATF2 expression was associated with metastatic specimens (P < 0.0001) and with poor survival (P = 0.0008). Patients who had both weak cytoplasmic and strong nuclear ATF2 staining had the worst outcome, both among the full cohort of patients (P < 0.0001) and among the patients with localized disease (n = 269; P < 0.0001). On multivariate analysis of the primary cutaneous specimens, weak cytoplasmic staining and strong nuclear staining was an independent predictor of poor outcome, as was Clark level. Nuclear ATF2 is likely to be transcriptionally active, whereas cytoplasmic ATF2 probably represents an inactive form. These findings support other preclinical findings in which transcriptionally active ATF2 is involved in tumor progression-proliferation in melanoma. Moreover, our findings suggest that ATF2 might be a useful prognostic marker in early-stage melanoma.
This article has been cited by other articles:
|
|
 |
|
  S. A. Aziz, M. Davies, E. Pick, C. Zito, L. Jilaveanu, R. L. Camp, D. L. Rimm, Y. Kluger, and H. M. Kluger Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma Clin. Cancer Res., May 1, 2009; 15(9): 3029 - 3036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. KNIPPEN, T. LONING, V. MULLER, C. SCHRODER, F. JANICKE, and K. MILDE-LANGOSCH Expression and Prognostic Value of Activating Transcription Factor 2 (ATF2) and its Phosphorylated Form in Mammary Carcinomas Anticancer Res, January 1, 2009; 29(1): 183 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shimizu, M. Shimoda, T. Yamaguchi, K.-H. Seong, T. Okamura, and S. Ishii Drosophila ATF-2 Regulates Sleep and Locomotor Activity in Pacemaker Neurons Mol. Cell. Biol., October 15, 2008; 28(20): 6278 - 6289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhoumik, N. Singha, M. J. O'Connell, and Z. A. Ronai Regulation of TIP60 by ATF2 Modulates ATM Activation J. Biol. Chem., June 20, 2008; 283(25): 17605 - 17614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhoumik, B. Fichtman, C. DeRossi, W. Breitwieser, H. M. Kluger, S. Davis, A. Subtil, P. Meltzer, S. Krajewski, N. Jones, et al. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer PNAS, February 5, 2008; 105(5): 1674 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Abbas, A. Bhoumik, R. Dahl, S. Vasile, S. Krajewski, N. D.P. Cosford, and Z. A. Ronai Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma Clin. Cancer Res., November 15, 2007; 13(22): 6769 - 6778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bandyopadhyay, Y. Wang, R. Zhan, S. K. Pai, M. Watabe, M. Iiizumi, E. Furuta, S. Mohinta, W. Liu, S. Hirota, et al. The Tumor Metastasis Suppressor Gene Drg-1 Down-regulates the Expression of Activating Transcription Factor 3 in Prostate Cancer Cancer Res., December 15, 2006; 66(24): 11983 - 11990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Becker, M. C. Mihm, S. M. Hewitt, V. K. Sondak, J. W. Fountain, and M. Thurin Markers and Tissue Resources for Melanoma: Meeting Report. Cancer Res., November 15, 2006; 66(22): 10652 - 10657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Hodi Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage Clin. Cancer Res., February 1, 2006; 12(3): 673 - 678. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kluger, D. Chelouche Lev, Y. Kluger, M. M. McCarthy, G. Kiriakova, R. L. Camp, D. L. Rimm, and J. E. Price Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease Cancer Res., July 1, 2005; 65(13): 5578 - 5587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Berger, R. L. Camp, K. A. DiVito, H. M. Kluger, R. Halaban, and D. L. Rimm Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome Cancer Res., December 1, 2004; 64(23): 8767 - 8772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. DiVito, A. J. Berger, R. L. Camp, M. Dolled-Filhart, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma Cancer Res., December 1, 2004; 64(23): 8773 - 8777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoek, D. L. Rimm, K. R. Williams, H. Zhao, S. Ariyan, A. Lin, H. M. Kluger, A. J. Berger, E. Cheng, E. S. Trombetta, et al. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas Cancer Res., August 1, 2004; 64(15): 5270 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhoumik, N. Jones, and Z. Ronai Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity PNAS, March 23, 2004; 101(12): 4222 - 4227. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
